Welcome to our dedicated page for American Ventures Acquisition I SEC filings (Ticker: AVAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on American Ventures Acquisition I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into American Ventures Acquisition I's regulatory disclosures and financial reporting.
American Ventures Acquisition Corp. I, a Florida-based blank check company, is planning an initial public offering of 20,000,000 shares of Class A common stock at $5.00 per share, for gross proceeds of $100,000,000, with underwriters holding an option to buy up to 3,000,000 additional shares. The company is a SPAC formed to complete a business combination, targeting primarily U.S.-based businesses that support domestic manufacturing, technology, healthcare, logistics and critical supply chains, with a stated goal of finding a target with an enterprise value of about $700 million or more. At least $100,000,000 of IPO and private placement proceeds (or $115,000,000 if the over-allotment is fully exercised) will be placed in a trust account at $5.00 per public share for the benefit of public stockholders.
The sponsor has purchased 23,000,000 founder shares of Class B common stock for $25,000 (about $0.001 per share) and has committed to buy 740,000 private shares (up to 800,000) at $5.00 per share, leading to substantial dilution for public stockholders and preserving roughly 50% post-IPO ownership for the sponsor and its affiliates through anti-dilution rights. Public investors will be able to redeem their shares for cash held in the trust in connection with the initial business combination or if no deal is completed within 18 months of the IPO closing (extendable to 24 months upon signing a definitive agreement, and potentially further with stockholder approval). The filing highlights multiple potential conflicts of interest, including low-cost founder equity, monthly payments of $20,000 to an affiliate of the sponsor, up to $2,500,000 in convertible working capital loans, and overlapping SPAC and corporate roles across the sponsor, management team, directors and advisory board.